4/16
08:02 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $25.00 price target on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) is now covered by analysts at Chardan Capital. They set a "buy" rating and a $25.00 price target on the stock.
4/1
07:30 am
krro
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
High
Report
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
3/20
08:05 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
High
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
3/19
10:45 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at Royal Bank of Canada from $105.00 to $95.00. They now have an "outperform" rating on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its price target lowered by analysts at Royal Bank of Canada from $105.00 to $95.00. They now have an "outperform" rating on the stock.
3/19
07:07 am
krro
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? [Yahoo! Finance]
Low
Report
Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth? [Yahoo! Finance]
3/18
07:00 am
krro
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Medium
Report
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
3/14
08:00 am
krro
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Low
Report
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
2/26
08:00 am
krro
Korro to Present at the TD Cowen 45th Annual Health Care Conference
Low
Report
Korro to Present at the TD Cowen 45th Annual Health Care Conference